At the record breaking ESMO 2025 Congress in Berlin, PRIME-ROSE partners once again came together to showcase the power of European collaboration in advancing precision cancer medicine. Building on previous year’s momentum, our joint activities included scientific presentations, interactive sessions, and strategic meetings highlighting the impact of our work to translational research and patient care across borders.

The congress provided a valuable platform to share insights, foster new connections, and reinforce our commitment to improving cancer care through data-driven innovation and multidisciplinary cooperation.

In parallel, PRIME-ROSE continues its active collaboration within the EU4Health Joint Action on Precision Cancer Medicine (JAPCM), where recent roundtable discussions both with academic and pharma representatives emphasized the importance of aligning national efforts to ensure equitable access to personalized oncology across Europe.

‍